Dianthus Therapeutics, Inc.
DNTH
$43.97
$1.694.00%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -88.32% | -102.46% | -100.61% | -95.08% | -55.64% |
| Total Depreciation and Amortization | -6.41% | 4.41% | 14.96% | 16.06% | 45.18% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 125.40% | 100.78% | 205.85% | 355.52% | 302.23% |
| Change in Net Operating Assets | 351.12% | 1,346.85% | -85.39% | -107.22% | -120.13% |
| Cash from Operations | -74.98% | -95.33% | -118.87% | -112.09% | -84.86% |
| Capital Expenditure | -26.19% | -1.61% | 24.22% | 4.55% | 34.88% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 32.67% | -906.47% | -8,079.74% | -1,507.98% | -1,803.99% |
| Cash from Investing | 32.65% | -901.81% | -7,773.29% | -1,516.15% | -1,818.41% |
| Total Debt Issued | -- | -- | -- | -- | -100.00% |
| Total Debt Repaid | -- | -- | -- | -- | 100.00% |
| Issuance of Common Stock | 36.63% | -82.33% | -82.55% | 5,405,660.00% | 4,612,140.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 99.12% | -100.00% | -101.85% | -110.98% | -114.11% |
| Cash from Financing | 49.19% | -88.35% | -89.20% | 91.37% | 52.47% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 118.02% | -209.84% | -204.22% | -193.50% | -202.53% |